News
Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease
New York/London, 18 August, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent...
Tiziana Life Sciences to Present at BTIG’s Virtual Biotechnology Conference
NEW YORK and LONDON, August 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, announced that members of its...
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences PLC 1b. Please...
Closing of $57.25 Million Offering
London, New York 5 August 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces the closing of its...
Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients
Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients Recently signed agreements with four contract research organizations (“CROs”) to...
Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million
New York and London, August 3, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the "Company" or "Tiziana"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced it has entered into...
Total Voting Rights
London, New York, 31 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...
Tiziana Announces Submission of a Patent Application for Nasal Administration of Foralumab, A Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients
New York/London, July 31, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has...
Early notification of proposed admission to the Official List and cancellation of trading on AIM
Tiziana Life Sciences plc the dual listed (NASDAQ:TLSA & UK AIMS:TILS) today announces its intention to apply for admission to listing of its ordinary shares (the "Ordinary Shares") on the standard listing segment of the Official List of the Financial Conduct...
Update on Timings and Corporate Actions
New York/London, 30 July 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, gives the following updates on...
Investor Webinar to Provide Corporate Updates and Q&A Session on July 30, 2020
NEW YORK/LONDON, July 30, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced that Kunwar Shailubhai,...
Exercise of Warrants and Issue of Equity and Total Voting Rights
London, New York, 24 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has allotted and...
Director Appointment
New York/London, 20 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, is pleased to announce the...
Results of Annual General Meeting
London, New York, 16 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...
Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy
New York/London, July 16, 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, is pleased to announce that it has...
Change to ADS Ratio – Updated
New York/London, 15 July 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt ("ADR") programme. Please note that pursuant to the announcement earlier today, to effect the...
Change to ADS Ratio
New York/London, 15 July 2020 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS, NASDAQ: TLSA), announces a ratio change to its sponsored Level 3 American Depositary Receipt ("ADR") programme. This corporate action, which is a 2.5 for 1 forward split for the purposes...
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
NEW YORK and LONDON, July 10, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announced an interview with...
Total Voting Rights and StemPrintER demerger update
London, New York, 1 July 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...
Agreement with STC Biologics for GMP Manufacturing of an anti-Interleukin-6-Receptor Monoclonal Antibody for Clinical Studies in Patients with COVID-19.
This proprietary inhalation technology for direct delivery of mAbs or other small molecule drugs such as Remdesivir® (Roche) to lungs could potentially be a transformational therapy for developing a rapid treatment for COVID-19 New York/London – 29 June 2020 – Tiziana...
Annual General Meeting
London, New York, 23 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...
Exercise of Warrants and Issue of Equity and Total Voting Rights
London, New York, 22 June 2020 - Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the "Company" or "Tiziana"), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology,...
Patent Granted for Oral Administration
Tiziana Granted First-Ever Patent on a Transformational Technology for Oral Delivery of all Anti-CD3 Monoclonal Antibodies for Treatment of Human Diseases First-ever granted patent on oral administration of anti-CD3 monoclonal antibodies for immunotherapies...
Directorate Change
London / New York, 18 June 2020 - Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS), the U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces Gregor MacRae...